Using cerium oxide nanoparticles to improve imaging and treatment for inflammatory bowel disease
Cerium oxide nanoparticles for CT imaging and catalytic therapeutic intervention in inflammatory bowel disease
['FUNDING_R01'] · UNIVERSITY OF PENNSYLVANIA · NIH-11017936
This study is exploring a new type of tiny particles called cerium oxide nanoparticles to see if they can help improve CT scans for people with inflammatory bowel disease (IBD) by making it easier to spot inflammation and possibly even help reduce it.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PENNSYLVANIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11017936 on ClinicalTrials.gov |
What this research studies
This research investigates the use of cerium oxide nanoparticles as a new contrast agent for computed tomography (CT) imaging specifically targeting inflammatory bowel disease (IBD). Traditional contrast agents like iodine and barium are not effective in pinpointing inflammation, making diagnosis challenging. The study aims to enhance imaging accuracy by using dextran-coated cerium oxide nanoparticles, which have shown promise in accumulating at inflammation sites. Additionally, these nanoparticles may also possess anti-inflammatory properties, potentially offering a new therapeutic option for patients with IBD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who require imaging and treatment.
Not a fit: Patients without inflammatory bowel disease or those who do not require imaging may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate diagnoses and improved treatment options for patients suffering from inflammatory bowel disease.
How similar studies have performed: While the use of cerium oxide nanoparticles in this context is relatively novel, preliminary data suggests potential success in similar applications.
Where this research is happening
PHILADELPHIA, UNITED STATES
- UNIVERSITY OF PENNSYLVANIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CORMODE, DAVID PETER — UNIVERSITY OF PENNSYLVANIA
- Study coordinator: CORMODE, DAVID PETER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.